- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04731870
Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines
Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines Among a Cross-section of US Healthcare Providers and Key At-risk Subgroups in the Rural South
The COVID-19 pandemic has highlighted deleterious US health inequities. Specifically, African Americans, Latinos, and Native Americans have and continue to shoulder a greater burden of COVID-19 infections and deaths in the US. In addition to existing racial and ethnic disparities are rural health and regional disparities. Given the disproportionate impact of disease in US communities of color and also in rural and southern regions of the US, there is no doubt that these at-risk subgroups will continue to experience higher rates of coronavirus-related mortality as well as other long-term health outcomes as compared to other US populations.
It is unknown how healthcare providers and other key at-risk subgroups within the US will receive COVID-19 vaccines. For success in immunizations, the US will need to reach their most at-risk and vulnerable populations. In addition to at-risk populations, a successful immunization strategy will involve engaging providers to support clear, consistent, and strong vaccine recommendation. It is critical to build vaccine trust, confidence, and overall acceptance of COVID-19 vaccines among healthcare providers and key at-risk subgroups, especially given the accelerated production timeline of these vaccines. Likewise, tailored vaccine messaging for key subgroups is vital in achieving vaccine confidence and trust.
The proposed study will explore perceptions, confidence, trust, and uptake of potential COVID-19 vaccines among healthcare providers (nurses and doctors) and key at-risk population subgroups (minority populations living in the rural south) and will develop and test vaccine messaging that boosts vaccine confidence and trust among these key at-risk subgroups.
Study Overview
Detailed Description
Study objectives are as follows: Objective 1: To assess COVID-19 perceptions, COVID-19 vaccine confidence, projected vaccine recommendation practices, and trust in the health system and public health authorities among a cross-section of healthcare providers in the US (nurses and physicians); Objective 2: To assess COVID-19 perceptions, COVID-19 vaccine confidence, projected vaccine uptake, and trust in the health system, in healthcare providers, and in public health authorities among key at-risk subgroups in the US (minority populations living in the rural south); and Objective 3: To develop, tailor, and test COVID-19 vaccine messaging to boost vaccine confidence and trust, and COVID-19 preventive behavior, among at-risk subgroups in the US (minority populations living in the rural south). Perceptions, confidence, uptake, and trust in potential COVID-19 vaccines will be assessed among four identified and distinct groups via a quantitative and electronic survey and qualitative focus groups with key at-risk subgroups will be utilized to develop, tailor, and test COVID-19 vaccine messaging for at-risk subgroups.
This study will: 1) provide important national-level data regarding healthcare provider vaccine perceptions, confidence, trust, and projected vaccine recommendation practices for COVID-19, 2) ascertain vaccine perceptions, confidence, trust, and projected uptake of potential COVID-19 vaccines among at-risk populations in the US, and 3) develop tailored messaging for at-risk populations that can be used to boost vaccine confidence and trust, and preventive behaviors, among these high-risk groups in the coming years. This study will help to inform a larger coordinated national promotion strategy and campaign that can work to effectively communicate with the public about potential COVID-19 vaccines.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Alice R Richman, PhD
- Phone Number: 252-328-6431
- Email: richmana@ecu.edu
Study Locations
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- Carol Belk Building
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Nurses (at least 50% from the south),
- Primary Care/Family Physicians (at least 50% from the south),
- Rural, low-income, minority men and women living in the south (income of $25K per year or less and 70% of respondents will be Black, Latina, or Native American) and
- Urban, low-income minority men and women living in the south (income of $25K per year or less and 70% of respondents will be Black, Latina, or Native American).
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nurses/Doctors
Covid-19 vaccine confidence and recommendation practices of nurses/doctors
|
This is not an intervention study.
It involves social science research of surveys and focus groups.
|
Minority populations living in rural south
Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
|
This is not an intervention study.
It involves social science research of surveys and focus groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Covid-19 vaccine confidence (survey to be developed by study team)
Time Frame: year 1
|
Confidence in the Covid-19 vaccine efficacy and safety among a cross-section of healthcare providers and key at-risk subgroups in the US
|
year 1
|
Covid-19 vaccine messaging (messages to be developed by study team & focus group participants)
Time Frame: year 2
|
COVID-19 vaccine messaging (e.g. one or two sentences of culturally appropriate messages) that can be used to boost vaccine confidence and trust, and COVID-19 preventive behavior, among at-risk subgroups in the US (minority populations living in the rural south).
|
year 2
|
Covid-19 vaccine uptake (survey to be developed by study team)
Time Frame: year 1
|
COVID-19 vaccine uptake or projected uptake among a cross-section of healthcare providers and key at-risk subgroups in the US
|
year 1
|
Covid-19 vaccine trust (survey to be developed by study team)
Time Frame: year 1
|
COVID-19 vaccine trust in the health system and public health authorities a cross-section of healthcare providers and key at-risk subgroups in the US
|
year 1
|
Covid-19 vaccine recommendation practices (survey to be developed by study team)
Time Frame: year 1
|
COVID-19 vaccine recommendation practices among a cross-section of healthcare providers in the US
|
year 1
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Becky Welch, CPA, Assistant Vice Chancellor for Research Administration & Finance
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 60622
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus
-
Salvacion USA Inc.Completed
-
Janssen Vaccines & Prevention B.V.Completed
-
Texas A&M UniversityM.D. Anderson Cancer Center; Baylor College of Medicine; Cedars-Sinai Medical... and other collaboratorsActive, not recruitingCoronavirus Infection | Coronavirus | Coronavirus as the Cause of Diseases Classified ElsewhereUnited States
-
Beijing Ditan HospitalUnknown
-
Qilu Hospital of Shandong UniversityRecruitingCoronavirus | Traditional Chinese MedicineChina
-
Maimonides Medical CenterTerminatedCOVID, CoronavirusUnited States
-
CHU de ReimsCompletedCORONAVIRUS INFECTIONSFrance
-
NPO PetrovaxCompletedInfections, CoronavirusBelarus, Russian Federation
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
Bursa Yüksek İhtisas Education and Research HospitalUnknownCoronavirus as the Cause of Diseases Classified ElsewhereTurkey
Clinical Trials on Survey research
-
Ankara City Hospital BilkentCompleted
-
Tokat Gaziosmanpasa UniversityCompletedDental Anxiety | Dental Pain | Validation | Child Drawing Hospital ScaleTurkey
-
Stanford UniversityTerminatedRectal Cancer | Colon Cancer | Anal CancerUnited States
-
ANRS, Emerging Infectious DiseasesProgramme PAC-CI; Centre Population et Développement (CEPED/IRD)Recruiting
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Fred Hutchinson Cancer CenterRecruiting
-
Case Comprehensive Cancer CenterNational Institutes of Health (NIH); National Institute of Environmental Health...Not yet recruiting
-
Institut de Recherches Cliniques de MontrealCompleted
-
EusaPharma (UK) LimitedUniversity of Sheffield (ScHARR); KMC Health Care; Castleman Disease Collaborative...Not yet recruitingIdiopathic Multicentric Castleman's Disease
-
Necmettin Erbakan UniversityRecruitingRetinopathy of Prematurity | NewbornTurkey